

| | | | | |
|-----|-------------|-------------|------------|-------------|
| C26 | -0.3592 (6) | 0.6339 (9) | 1.1530 (3) | 0.072 (2) |
| C27 | -0.3542 (5) | 0.4039 (11) | 1.2611 (3) | 0.070 (2) |
| C28 | 0.5318 (5) | -0.4887 (9) | 0.6425 (3) | 0.035 (2) |
| C29 | 0.4497 (4) | -0.6243 (9) | 0.6192 (3) | 0.0342 (14) |
| C30 | 0.3739 (4) | -0.5494 (8) | 0.5685 (3) | 0.033 (2) |
| C31 | 0.3763 (4) | -0.3442 (8) | 0.5423 (2) | 0.0231 (13) |
| C32 | 0.4588 (4) | -0.2158 (8) | 0.5648 (3) | 0.039 (2) |
| C33 | 0.5377 (5) | -0.2873 (9) | 0.6142 (3) | 0.037 (2) |
| C34 | 0.6107 (5) | -0.5653 (9) | 0.7001 (3) | 0.052 (2) |

Table 2. Selected geometric parameters (\AA , $^\circ$)

| | | | |
|-------------|-----------|-------------|-----------|
| S—O1 | 1.415 (3) | C20—C21 | 1.519 (6) |
| S—O2 | 1.414 (3) | C20—C22 | 1.519 (6) |
| S—O3 | 1.567 (4) | C22—C23 | 1.504 (7) |
| S—C31 | 1.722 (5) | C23—C24 | 1.504 (6) |
| O1—C3 | 1.469 (5) | C24—C25 | 1.496 (7) |
| C5—C6 | 1.312 (6) | C25—C27 | 1.494 (6) |
| C17—C20 | 1.518 (7) | C25—C26 | 1.505 (7) |
| O3—S—O2 | 119.4 (2) | C21—C20—C22 | 110.1 (4) |
| O3—S—O1 | 104.1 (2) | C23—C22—C20 | 116.8 (5) |
| O2—S—O1 | 110.2 (2) | C22—C23—C24 | 115.4 (5) |
| O3—S—C31 | 110.6 (2) | C25—C24—C23 | 116.6 (5) |
| O2—S—C31 | 108.8 (3) | C27—C25—C24 | 111.0 (5) |
| O1—S—C31 | 102.4 (2) | C27—C25—C26 | 111.6 (5) |
| C17—C20—C21 | 114.4 (4) | C24—C25—C26 | 112.4 (5) |
| C17—C20—C22 | 112.2 (4) | | |
| C31—S—O1—C3 | 68.6 (4) | | |

The unit-cell and intensity data were collected on a Delft Instruments FAST diffractometer using the routines *ENDEX*, *REFINE* and *MADONL* in the *MADNES* software (Pflugrath & Messerschmidt, 1989) and processed using *ABSMAD* (Karaulov, 1992); detailed procedures are described by Darr, Drake, Hursthouse & Malik (1993). The non-H atoms were refined with anisotropic displacement parameters and H atoms were allowed to ride on their attached C atoms with a common isotropic displacement parameter.

Data collection: *MADNES* (Pflugrath & Messerschmidt, 1989). Cell refinement: *ABSMAD* (Karaulov, 1992). Program(s) used to solve structure: *SHELXS86* (Sheldrick, 1990). Program(s) used to refine structure: *SHELXL93* (Sheldrick, 1993). Molecular graphics: *ZORTEP* (Zsolnai, 1995).

The use of the EPSRC X-ray Crystallographic Service at The University of Wales, Cardiff, is gratefully acknowledged.

Lists of structure factors, anisotropic displacement parameters, H-atom coordinates and complete geometry have been deposited with the IUCr (Reference: BM1066). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

References

- Buchanan, H. J., Cox, P. J. & Wardell, J. L. (1996a). *J. Chem. Cryst.* In the press.
 Buchanan, H. J., Cox, P. J. & Wardell, J. L. (1996b). In preparation.
 Chandross, R. J. & Bordner, J. (1977). *Acta Cryst.* B33, 2934–2937.
 Cosier, J. & Glazer, A. M. (1986). *J. Appl. Cryst.* 19, 105–107.
 Darr, J. A., Drake, S. R., Hursthouse, M. B. & Malik, K. M. A. (1993). *Inorg. Chem.* 32, 5704–5708.
 El-Shora, A. I., Palmer, R. A., Singh, H., Bhardwaj & Paul, T. R. (1984). *J. Crystallogr. Spectrosc. Res.* 14, 89–115.
 Flack, H. D. (1983). *Acta Cryst.* A39, 876–881.

- Karaulov, A. I. (1992). *ABSMAD. Program for FAST Data Processing*. University of Wales, Cardiff, Wales.
 Pflugrath, J. W. & Messerschmidt, A. (1989). *MADNES*. Version 11 September, 1989. Distributed by Delft Instruments, Delft, The Netherlands.
 Sheldrick, G. M. (1990). *Acta Cryst.* A46, 467–473.
 Sheldrick, G. M. (1993). *SHELXL93. Program for the Refinement of Crystal Structures*. University of Göttingen, Germany.
 Wallis, E. S., Fernholz, E. & Gephart, F. T. (1937). *J. Am. Chem. Soc.* 59, 137–140.
 Zsolnai, L. (1995). *ZORTEP. An Interactive ORTEP Program*. University of Heidelberg, Germany.

Acta Cryst. (1996). C52, 2113–2115

Naphtho[2,3-*b*]cholestane

MASOOD PARVEZ, ROBERT NICHOLSON, DAN SIMION AND TED S. SORENSEN

Department of Chemistry, The University of Calgary, 2500 University Drive NW, Calgary, Alberta, Canada, T2N 1N4.
 E-mail: parvez@acs.ucalgary.ca


(Received 8 February 1996; accepted 13 March 1996)

Abstract

The crystal structure of the title compound, naphtho[2,3-*b*]cholestane, $C_{35}H_{50}$, is composed of independent molecules with normal molecular dimensions and no unusual contacts shorter than van der Waals distances.

Comment

In the course of our studies on the direct asymmetric introduction of a tricarbonylchromium moiety on prochiral arenes, we required pure optically active naphthalene ligands. The title compound, (1), has eight asymmetric centres and fulfills some of the requirements for a good chiral auxiliary: (i) good leaving-group ability, (ii) stable chiral information and (iii) easy recovery. In this paper, we report the crystal structure of the title compound. We did not determine the absolute configuration by X-ray methods, but the absolute configuration of the dibromo-cholestane has been established (Geise & Romers, 1966) and the structure and coordinates reported here refer to the same absolute configuration.






Fig. 1. ORTEPII (Johnson, 1976) drawing of the title compound with the atomic numbering scheme. Displacement ellipsoids are plotted at the 50% probability level; H atoms have been assigned arbitrary radii.

Fig. 1 shows the ORTEPII (Johnson, 1976) drawing of (1) in which a naphthyl group has been fused to cholestan-3-one at ring A. The molecular dimensions in (1) are unexceptional with mean bond distances: Csp^3-Csp^3 1.53 (3), Csp^3-Csp^2 1.50 (1) and C—C(aromatic) 1.39 (3) Å. The bond angles are also within error limits of the expected values. The molecular dimensions in (1) correspond closely with the molecular dimensions reported for 2,3-dibromo- and 2,3-dichlorocholestan-3-one (Geise & Romers, 1966).

The naphthyl moiety is essentially planar with maximum deviation of atoms from the least-squares planes being 0.03 (1) Å. The ring A of cholestan-3-one adopts a flattened chair conformation owing to the rigid naphthalene ring. The rings B and C of the steroid are in almost ideal chair conformations. The cyclopentane ring D adopts a C(13)-envelope conformation. The aliphatic chain that extends off ring D is a fully extended arm and has a *transoid* conformation along the entire chain.

Experimental

The title compound was prepared from 5 α -cholestane-3-one in four steps according to a modified literature method (Tius & Gomez-Saleno, 1986). Hydroxymethylation with ethyl formate followed by treatment with the trimethylchlorosilane-tertiary amine system gave 5 α -2-[{(trimethylsilyl)oxy}methylene]-cholestan-3-one. The 1,2-addition of benzyl magnesium chloride followed by treatment with pyridinium *p*-toluenesulfonate gave 5 α -3-benzyl-2-formyl-cholest-2-ene, which is easily aromatized in the presence of TiCl₄ to the title compound. Purification by flash chromatography (SiO₂/hexanes) and subsequent recrystallization from hexane gave naphtho[2,3-*b*]cholestan-3-one, (1).

Crystal data

$C_{35}H_{50}$
 $M_r = 470.78$

Mo $K\alpha$ radiation
 $\lambda = 0.71069$ Å

Monoclinic
 $P2_1$
 $a = 6.553$ (4) Å
 $b = 10.893$ (4) Å
 $c = 20.492$ (2) Å
 $\beta = 94.09$ (2) $^\circ$
 $V = 1459.0$ (8) Å³
 $Z = 2$
 $D_v = 1.072$ Mg m⁻³
 D_m not measured

Cell parameters from 21 reflections
 $\theta = 9.0-12.0$ $^\circ$
 $\mu = 0.059$ mm⁻¹
 $T = 296$ K
Plate
 $0.60 \times 0.45 \times 0.15$ mm
Colourless

Data collection

Rigaku AFC-6S diffractometer
 $w/2\theta$ scans
Absorption correction:
 ψ -scans (North, Phillips & Mathews, 1968)
 $T_{min} = 0.781$, $T_{max} = 1.000$
2981 measured reflections
2730 independent reflections

1175 observed reflections [$I > 3.0\sigma(I)$]
 $R_{int} = 0.0453$
 $\theta_{max} = 25.0$ $^\circ$
 $h = 0 \rightarrow 7$
 $k = 0 \rightarrow 12$
 $l = -24 \rightarrow 24$
3 standard reflections monitored every 200 reflections
intensity decay: 0.12%

Refinement

Refinement on F
 $R = 0.0595$
 $wR = 0.0611$
 $S = 3.158$
1175 reflections
317 parameters
H atoms riding, C—H 0.95 Å
 $w = 1/[\sigma^2(F_o) + 0.020(F_o^2)]$
 $(\Delta/\sigma)_{max} = 0.031$
 $\Delta\rho_{max} = 0.18$ e Å⁻³
 $\Delta\rho_{min} = -0.16$ e Å⁻³

Extinction correction:
Zachariasen type 2
Gaussian isotropic (Zachariasen, 1968)
Extinction coefficient: 13.41504
Atomic scattering factors from International Tables for X-ray Crystallography (1974, Vol. IV)

Table 1. Fractional atomic coordinates and equivalent isotropic displacement parameters (\AA^2)

| | x | y | z | U_{eq} |
|-------|-------------|-------------|------------|-----------------|
| C(1) | 0.9657 (9) | 0.0888 (6) | 0.8272 (3) | 0.047 (2) |
| C(2) | 0.9204 (9) | -0.0299 (6) | 0.8612 (3) | 0.050 (2) |
| C(3) | 0.7392 (9) | -0.0436 (6) | 0.8958 (3) | 0.053 (2) |
| C(4) | 0.5822 (9) | 0.0564 (6) | 0.8932 (3) | 0.063 (2) |
| C(5) | 0.6625 (9) | 0.1823 (5) | 0.8718 (3) | 0.048 (2) |
| C(6) | 0.4911 (9) | 0.2756 (6) | 0.8662 (3) | 0.057 (2) |
| C(7) | 0.5638 (9) | 0.4019 (6) | 0.8468 (3) | 0.054 (2) |
| C(8) | 0.6753 (9) | 0.3956 (6) | 0.7840 (3) | 0.049 (2) |
| C(9) | 0.8541 (9) | 0.3019 (6) | 0.7931 (3) | 0.047 (2) |
| C(10) | 0.7825 (9) | 0.1709 (5) | 0.8115 (3) | 0.044 (2) |
| C(11) | 0.9786 (9) | 0.3018 (6) | 0.7303 (3) | 0.063 (2) |
| C(12) | 1.0522 (9) | 0.4337 (6) | 0.7142 (3) | 0.056 (2) |
| C(13) | 0.8761 (9) | 0.5221 (6) | 0.7039 (3) | 0.050 (2) |
| C(14) | 0.7606 (9) | 0.5204 (5) | 0.7666 (3) | 0.050 (2) |
| C(15) | 0.6159 (9) | 0.6293 (6) | 0.7592 (3) | 0.065 (2) |
| C(16) | 0.7355 (9) | 0.7261 (6) | 0.7245 (3) | 0.059 (2) |
| C(17) | 0.9285 (9) | 0.6603 (6) | 0.6993 (3) | 0.053 (2) |
| C(18) | 0.7339 (9) | 0.4872 (6) | 0.6418 (3) | 0.063 (2) |
| C(19) | 0.6480 (9) | 0.1113 (6) | 0.7526 (3) | 0.058 (2) |
| C(20) | 1.0021 (10) | 0.7164 (6) | 0.6374 (3) | 0.066 (2) |
| C(21) | 1.1732 (11) | 0.6470 (7) | 0.6078 (4) | 0.090 (3) |
| C(22) | 1.0650 (11) | 0.8508 (7) | 0.6505 (4) | 0.095 (3) |
| C(23) | 1.1242 (14) | 0.9208 (8) | 0.5896 (4) | 0.112 (3) |
| C(24) | 1.1774 (14) | 1.0539 (8) | 0.6036 (5) | 0.120 (4) |
| C(25) | 1.2751 (16) | 1.1233 (9) | 0.5528 (4) | 0.122 (4) |
| C(26) | 1.2745 (21) | 1.2539 (9) | 0.5634 (5) | 0.210 (6) |
| C(27) | 1.4855 (16) | 1.0731 (14) | 0.5439 (5) | 0.206 (6) |
| C(28) | 1.0600 (9) | -0.1263 (6) | 0.8637 (3) | 0.046 (2) |
| C(29) | 1.0342 (9) | -0.2362 (6) | 0.8993 (3) | 0.051 (2) |
| C(30) | 1.1759 (9) | -0.3325 (6) | 0.9017 (3) | 0.051 (2) |
| C(31) | 1.1445 (10) | -0.4347 (6) | 0.9359 (3) | 0.064 (2) |
| C(32) | 0.9662 (10) | -0.4493 (6) | 0.9691 (3) | 0.059 (2) |
| C(33) | 0.8246 (10) | -0.3588 (7) | 0.9664 (3) | 0.060 (2) |
| C(34) | 0.8540 (9) | -0.2493 (6) | 0.9316 (3) | 0.049 (2) |
| C(35) | 0.7112 (9) | -0.1511 (7) | 0.9282 (3) | 0.059 (2) |

Space group $P2_1$ or $P2_1/m$ from the systematic absences $0k0$, $k = 2n + 1$; the former was chosen and confirmed by successful solution and refinement of the structure. The terminal C atoms C(26) and C(27) of the aliphatic chain exhibit large thermal motions showing a small degree of disorder.

Data collection: *MSCIAFC Diffractometer Control Software* (Molecular Structure Corporation, 1988). Cell refinement: *MSCIAFC Diffractometer Control Software*. Data reduction: *TEXSAN* (Molecular Structure Corporation, 1994). Program(s) used to solve structure: *SHELXS86* (Sheldrick, 1985). Program(s) used to refine structure: *TEXSAN*. Software used to prepare material for publication: *TEXSAN*.

The authors thank the Natural Sciences and Engineering Research Council (Canada) for providing the diffractometer through an equipment grant to the University of Calgary and financial support to TSS.

Lists of structure factors, anisotropic displacement parameters, H-atom coordinates and complete geometry have been deposited with the IUCr (Reference: FG1167). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

References

Geise, H. J. & Romers, C. (1966). *Acta Cryst.* **20**, 257–263.

- Johnson, C. K. (1976). *ORTEPII*. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
 Molecular Structure Corporation. (1988). *MSCIAFC. Diffractometer Control Software*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
 Molecular Structure Corporation. (1994). *TEXSAN. Single Crystal Structure Analysis Software*. MSC, 3200 Research Forest Drive, The Woodlands, TX 77381, USA.
 North, A. C. T., Phillips, D. C. & Mathews, F. S. (1968). *Acta Cryst.* **A24**, 351–359.
 Sheldrick, G. M. (1985). *SHELXS86. Program for the Solution of Crystal Structures*. University of Göttingen, Germany.
 Tius, M. A. & Gomez-Saleno, J. (1986). *Tetrahedron Lett.* **27**, 2571–2574.
 Zachariasen, W. H. (1968). *Acta Cryst.* **A24**, 212–216.

Acta Cryst. (1996). **C52**, 2115–2117

6-(3-Methylbenzyl)-2-(2-methylpropyl)thio-(3H)-pyrimidinone (DABO 622)

ALESSANDRO ETTORRE,^a ANTONELLO MAI,^b MARINO ARTICO,^b SILVIO MASSA,^c ANTONELLA DE MONTIS^d AND PAOLO LA COLLA^d

^aMenarini Ricerche S.p.A., via T. Speri 10, 00040 Pomezia (Roma), Italy, ^bDipartimento di Studi Farmaceutici, Facoltà di Farmacia, Università La Sapienza, P.le A. Moro 5, 00185 Roma, Italy, ^cDipartimento Farmaco Chimico Tecnologico, Università di Siena, via Banchi di Sotto 55, 53100 Siena, Italy, and ^dDipartimento di Biologia Sperimentale, Sezione di Microbiologia, Università di Cagliari, v.le Regina Margherita 45, 09124 Cagliari, Italy. E-mail: alex@isc.mlib.cnr.it

(Received 28 February 1996; accepted 13 May 1996)

Abstract

The title compound, $C_{16}H_{20}ON_2S$, shows the pyrimidine and benzene rings arranged in ‘butterfly-like’ conformation as observed for TIBO, nevirapine and other non-nucleoside inhibitors of HIV-1 Reverse Transcriptase.

Comment

Virally encoded reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) catalyses the retro-transcription of single-stranded viral RNA into double-stranded DNA before the viral genome is integrated into the DNA of the host cell (Mitsuya, Yarchoan & Broder, 1990). Currently two classes of anti-AIDS agents targeted at RT have been developed, *i.e.* nucleoside analogues such as AZT, ddC, ddI and D4T, which have been approved for the treatment of AIDS, and non-nucleoside inhibitors (NNRTIs). Among these, the first compounds described were TIBO, HEPT and nevirapine, followed by BHAP, PETT α -APA and, more recently, by DABO